• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
VLA
Click for more information
0.00% $1.75

VIRALYTICS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
VLAUS FDA pre-IND meeting updatePRICE SENSITIVE25/06/10
VLASection 708A(5)(e) Notice21/06/10
VLAAppendix 3B21/06/10
VLAAppendix 3B - Exercise of Listed Options16/06/10
VLAAppendix 3B - Exercise of Listed Options08/06/10
VLAAppendix 3B - Exercise of Listed Options01/06/10
VLAExpiry of Listed Options - mailing to option holders27/05/10
VLAAppendix 3B - Exercise of Listed Options21/05/10
VLASection 708A(5)(e) Notice18/05/10
VLAAppendix 3B - Partial Conversion of Convertible Note17/05/10
VLAFDA meeting date set for Phase II trial13/05/10
VLAAppendix 3B - Exercise of Listed Options11/05/10
VLAInvestor Presentation06/05/10
VLAAppendix 3B - Exercise of Listed Options23/04/10
VLAAppendix 3B - Exercise of Listed Options15/04/10
VLASection 708A(5)(e) Notice07/04/10
VLAAppendix 4C - quarterlyPRICE SENSITIVE07/04/10
VLAAppendix 3B - Partial Conversion of Convertible Note06/04/10
VLAAppendix 3B - Exercise of Listed Options01/04/10
VLAs708A(5)(e) Disclosure Notice - Issue of placement shares29/03/10
VLAAppendix 3B - Placement and Exercise of Listed Options26/03/10
VLAPlacementPRICE SENSITIVE25/03/10
VLAAppendix 3B23/03/10
VLAViralytics moves to increase US presence19/03/10
VLASection 708A(5)(e) Notice16/03/10
VLAAppendix 3B - Partial Conversion of Convertible Note15/03/10
VLABIO-Europe partneringONE Spring 2010 -VLA MD's presentation10/03/10
VLAAppendix 3B - Exercise of Listed Options03/03/10
VLAAppendix 4D and Half-Year Financial ReportPRICE SENSITIVE26/02/10
VLAAppendix 3B - Exercise of Listed Options17/02/10
VLASection 708A(5)(e) Notice10/02/10
VLAAppendix 3B - Partial Conversion of Convertible Note10/02/10
VLAChange of Sydney Office Address05/02/10
VLAAppendix 4C - quarterlyPRICE SENSITIVE29/01/10
VLASection 708A(5)(e) Notice28/01/10
VLAAppendix 3B - Partial Conversion of Convertible Note28/01/10
VLAAppendix 3B - Partial Conversion of Convertible Note21/01/10
VLASection 708A(5)(e) Notice21/01/10
VLAMelanoma Phase I Clinical Trial Report CompletedPRICE SENSITIVE19/01/10
VLASection 708A(5)(e) Notice13/01/10
VLAAppendix 3B - Partial Conversion of Convertible Note13/01/10
VLAAustralian echovirus family patent grantedPRICE SENSITIVE07/01/10
VLAHead and Neck trial dosing increasePRICE SENSITIVE18/12/09
VLAShare Registry - Change of Address11/12/09
VLAAppendix 3B02/12/09
VLAChange of Director's Interest Notice30/11/09
VLAResults of 2009 Annual General Meeting24/11/09
VLAManaging Director's address to the 2009 AGM24/11/09
VLALeading UK Oncologist joins VLA Clinical Advisory Board23/11/09
VLASection 708A(5)(e) Notice20/11/09
VLAAppendix 3B - Partial Conversion of Convertible Note20/11/09
VLASection 708A(5)(e) Notice19/11/09
VLAAppendix 3B - Partial Conversion of Convertible Note19/11/09
VLAViralytics Limited - Share Price MovementPRICE SENSITIVE19/11/09
VLAUS Corporate Presentation by VLA Managing Director11/11/09
VLASection 708A(5)(e) Notice10/11/09
VLAAppendix 3B - Partial Conversion of Convertible Note10/11/09
VLALeading US Virologist joins VLA Clinical Advisory Board06/11/09
VLAMelanoma, Breast and Prostate cancer IV trial - 2nd sitePRICE SENSITIVE02/11/09
VLAAppendix 4C - quarterlyPRICE SENSITIVE30/10/09
VLAHead and Neck cancer study additional site - Royal AdelaidePRICE SENSITIVE29/10/09
VLANotice of Annual General Meeting and Annual Report23/10/09
VLASection 708A(5)(e) Notice19/10/09
VLAAppendix 3B - Partial Conversion of Convertible Note19/10/09
VLASection 708A(5)(e) Notice12/10/09
VLAAppendix 3B - Partial Conversion of Convertable Note12/10/09
VLAHead and Neck Trial UpdatePRICE SENSITIVE08/10/09
VLAAnnual Report to shareholders30/09/09
VLAAppendix 3B partial conversion of Convertible Note24/09/09
VLASection 708A(5)(e) Notice24/09/09
VLAMelanoma trial completedPRICE SENSITIVE22/09/09
VLASection 708A(5)(e) Notice15/09/09
VLAAppendix 3B - Partial Conversion of Convertible Note15/09/09
VLAAppendix 3B - Partial Conversion of Convertible Note31/08/09
VLASection 708A(5)(e) Notice31/08/09
VLAPreliminary Final Report and FY2009 Statutory AccountsPRICE SENSITIVE31/08/09
VLASection 708A(5)(e) Notice24/08/09
VLAAppendix 3B - Partial Conversion of Convertible Note24/08/09
VLAShare Registry - Change of Address21/08/09
VLAResults of Extraordinary General Meeting21/08/09
VLAClinical Trial progress13/08/09
VLASection 708A(5)(e) Notice29/07/09
VLAAppendix 3B - Partial Conversion of Convertible Note29/07/09
VLAAppendix 4C - quarterlyPRICE SENSITIVE29/07/09
VLASection 708A(5)(e) Notice21/07/09
VLAAppendix 3B - Partial Conversion of Convertible Note21/07/09
VLASection 708A(5)(e) Notice17/07/09
VLAAppendix 3B - Partial Conversion of Convertible Note17/07/09
VLANotice of Meeting and Independent Expert's Report15/07/09
VLASection 708A(5)(e) Notice09/07/09
VLAAppendix 3B - Partial Conversion of Convertible Note09/07/09
VLAOptions Rights Issue Result and Capital Raising UpdatePRICE SENSITIVE01/07/09
VLAAppendix 3B01/07/09
VLAMailing to Shareholders17/06/09
VLAAppendix 3B - Convertible Note17/06/09
VLA$US6m convertible note facility signedPRICE SENSITIVE12/06/09
VLASupplementary ProspectusPRICE SENSITIVE01/06/09
VLASupplementary Prospectus issued and funding offer receivedPRICE SENSITIVE01/06/09
VLANon-Renounceable Issue - offer period extended25/05/09
VLADespatch of Prospectus08/05/09
VLAUS FDA pre-IND meeting update
25/06/10PRICE SENSITIVE
VLASection 708A(5)(e) Notice
21/06/10
VLAAppendix 3B
21/06/10
VLAAppendix 3B - Exercise of Listed Options
16/06/10
VLAAppendix 3B - Exercise of Listed Options
08/06/10
VLAAppendix 3B - Exercise of Listed Options
01/06/10
VLAExpiry of Listed Options - mailing to option holders
27/05/10
VLAAppendix 3B - Exercise of Listed Options
21/05/10
VLASection 708A(5)(e) Notice
18/05/10
VLAAppendix 3B - Partial Conversion of Convertible Note
17/05/10
VLAFDA meeting date set for Phase II trial
13/05/10
VLAAppendix 3B - Exercise of Listed Options
11/05/10
VLAInvestor Presentation
06/05/10
VLAAppendix 3B - Exercise of Listed Options
23/04/10
VLAAppendix 3B - Exercise of Listed Options
15/04/10
VLASection 708A(5)(e) Notice
07/04/10
VLAAppendix 4C - quarterly
07/04/10PRICE SENSITIVE
VLAAppendix 3B - Partial Conversion of Convertible Note
06/04/10
VLAAppendix 3B - Exercise of Listed Options
01/04/10
VLAs708A(5)(e) Disclosure Notice - Issue of placement shares
29/03/10
VLAAppendix 3B - Placement and Exercise of Listed Options
26/03/10
VLAPlacement
25/03/10PRICE SENSITIVE
VLAAppendix 3B
23/03/10
VLAViralytics moves to increase US presence
19/03/10
VLASection 708A(5)(e) Notice
16/03/10
VLAAppendix 3B - Partial Conversion of Convertible Note
15/03/10
VLABIO-Europe partneringONE Spring 2010 -VLA MD's presentation
10/03/10
VLAAppendix 3B - Exercise of Listed Options
03/03/10
VLAAppendix 4D and Half-Year Financial Report
26/02/10PRICE SENSITIVE
VLAAppendix 3B - Exercise of Listed Options
17/02/10
VLASection 708A(5)(e) Notice
10/02/10
VLAAppendix 3B - Partial Conversion of Convertible Note
10/02/10
VLAChange of Sydney Office Address
05/02/10
VLAAppendix 4C - quarterly
29/01/10PRICE SENSITIVE
VLASection 708A(5)(e) Notice
28/01/10
VLAAppendix 3B - Partial Conversion of Convertible Note
28/01/10
VLAAppendix 3B - Partial Conversion of Convertible Note
21/01/10
VLASection 708A(5)(e) Notice
21/01/10
VLAMelanoma Phase I Clinical Trial Report Completed
19/01/10PRICE SENSITIVE
VLASection 708A(5)(e) Notice
13/01/10
VLAAppendix 3B - Partial Conversion of Convertible Note
13/01/10
VLAAustralian echovirus family patent granted
07/01/10PRICE SENSITIVE
VLAHead and Neck trial dosing increase
18/12/09PRICE SENSITIVE
VLAShare Registry - Change of Address
11/12/09
VLAAppendix 3B
02/12/09
VLAChange of Director's Interest Notice
30/11/09
VLAResults of 2009 Annual General Meeting
24/11/09
VLAManaging Director's address to the 2009 AGM
24/11/09
VLALeading UK Oncologist joins VLA Clinical Advisory Board
23/11/09
VLASection 708A(5)(e) Notice
20/11/09
VLAAppendix 3B - Partial Conversion of Convertible Note
20/11/09
VLASection 708A(5)(e) Notice
19/11/09
VLAAppendix 3B - Partial Conversion of Convertible Note
19/11/09
VLAViralytics Limited - Share Price Movement
19/11/09PRICE SENSITIVE
VLAUS Corporate Presentation by VLA Managing Director
11/11/09
VLASection 708A(5)(e) Notice
10/11/09
VLAAppendix 3B - Partial Conversion of Convertible Note
10/11/09
VLALeading US Virologist joins VLA Clinical Advisory Board
06/11/09
VLAMelanoma, Breast and Prostate cancer IV trial - 2nd site
02/11/09PRICE SENSITIVE
VLAAppendix 4C - quarterly
30/10/09PRICE SENSITIVE
VLAHead and Neck cancer study additional site - Royal Adelaide
29/10/09PRICE SENSITIVE
VLANotice of Annual General Meeting and Annual Report
23/10/09
VLASection 708A(5)(e) Notice
19/10/09
VLAAppendix 3B - Partial Conversion of Convertible Note
19/10/09
VLASection 708A(5)(e) Notice
12/10/09
VLAAppendix 3B - Partial Conversion of Convertable Note
12/10/09
VLAHead and Neck Trial Update
08/10/09PRICE SENSITIVE
VLAAnnual Report to shareholders
30/09/09
VLAAppendix 3B partial conversion of Convertible Note
24/09/09
VLASection 708A(5)(e) Notice
24/09/09
VLAMelanoma trial completed
22/09/09PRICE SENSITIVE
VLASection 708A(5)(e) Notice
15/09/09
VLAAppendix 3B - Partial Conversion of Convertible Note
15/09/09
VLAAppendix 3B - Partial Conversion of Convertible Note
31/08/09
VLASection 708A(5)(e) Notice
31/08/09
VLAPreliminary Final Report and FY2009 Statutory Accounts
31/08/09PRICE SENSITIVE
VLASection 708A(5)(e) Notice
24/08/09
VLAAppendix 3B - Partial Conversion of Convertible Note
24/08/09
VLAShare Registry - Change of Address
21/08/09
VLAResults of Extraordinary General Meeting
21/08/09
VLAClinical Trial progress
13/08/09
VLASection 708A(5)(e) Notice
29/07/09
VLAAppendix 3B - Partial Conversion of Convertible Note
29/07/09
VLAAppendix 4C - quarterly
29/07/09PRICE SENSITIVE
VLASection 708A(5)(e) Notice
21/07/09
VLAAppendix 3B - Partial Conversion of Convertible Note
21/07/09
VLASection 708A(5)(e) Notice
17/07/09
VLAAppendix 3B - Partial Conversion of Convertible Note
17/07/09
VLANotice of Meeting and Independent Expert's Report
15/07/09
VLASection 708A(5)(e) Notice
09/07/09
VLAAppendix 3B - Partial Conversion of Convertible Note
09/07/09
VLAOptions Rights Issue Result and Capital Raising Update
01/07/09PRICE SENSITIVE
VLAAppendix 3B
01/07/09
VLAMailing to Shareholders
17/06/09
VLAAppendix 3B - Convertible Note
17/06/09
VLA$US6m convertible note facility signed
12/06/09PRICE SENSITIVE
VLASupplementary Prospectus
01/06/09PRICE SENSITIVE
VLASupplementary Prospectus issued and funding offer received
01/06/09PRICE SENSITIVE
VLANon-Renounceable Issue - offer period extended
25/05/09
VLADespatch of Prospectus
08/05/09
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
ASX Market Close: ASX closes above 8,400pts on green Wednesday | Nov 27, 2024 The ASX finished up around 8,400 points after flirting with the 8,410 level throughout the day, clearly, in a good mood.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.